Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Borevind AB (publ) in connection with issue in kind
Mandate

Vinge advises Borevind AB (publ) in connection with issue in kind

July 05, 2010

Vinge has advised Borevind in connection with an issue in kind regarding the entire issued shares of GenerPro AB and Energi Tekknik AS. Borevind invests in and improves unlisted companies which conduct operations relating to renewable energy and improvement of energy efficiency. Borevind’s shares are traded on NASDAQ OMX First North. GenerPro manufactures and renovates, among other things, generators and steam turbines for the power industry. The operations are conducted in Västerås. Energi Teknikk develops, manufactures and supplies small hydropower plants. The operations are conducted in Dimmelsvik in Norway.

Vinge’s team primarily consisted of associates Magnus Pauli, Anna Björk Larsson and Tove Rosén Johansson.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026